Investing in potentially the first cancer therapy to work in all tumours, irrespective of strain or mutation. 

We will be undertaking a Series A in 2021 for funding GMP readiness and final pre-clinicals to get authorisation to run our first-in-human PoC trials in a range of solid tumours.


If you are an interested investment fund please email us.

Proudly Supported by / Partnered with:

Merck kgaa logo.png
collaborate to Innovate logo.jpg
kizoo logo.png
EIT logo.png
Downing Ventures logo.png
KCL logo.png
BIA logo.png

Note: This website contains certain statements that are not historical facts and may be forward-looking statements, please see our legal notices.